Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer:a combined clinical-molecular pathological approach
| Data(s) |
01/10/2011
|
|---|---|
| Resumo |
Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols. |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Salto-Tellez , M , Tsao , M-S , Shih , J-Y , Thongprasert , S , Lu , S , Chang , G-C , Au , J S-K , Chou , T-Y , Lee , J-S , Shi , Y-K , Radzi , A , Kang , J-H , Kim , S-W , Tan , S-Y & Yang , J C-H 2011 , ' Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer : a combined clinical-molecular pathological approach ' Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , vol 6 , no. 10 , pp. 1663-9 . DOI: 10.1097/JTO.0b013e318227816a |
| Palavras-Chave | #Far East #Neoplasm Staging #Receptor, Epidermal Growth Factor #Antineoplastic Agents #Pathology, Molecular #DNA Mutational Analysis #Humans #Drug Resistance, Neoplasm #Asian Continental Ancestry Group #Individualized Medicine #Survival Rate #Lung Neoplasms #Treatment Outcome #Practice Guidelines as Topic #Carcinoma, Non-Small-Cell Lung #Mutation |
| Tipo |
article |
